<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FLUCONAZOLE <img border="0" src="../images/pr.gif"/></span><br/>(flu-con'a-zole)<br/><span class="topboxtradename">Diflucan<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">antifungal</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg, 100 mg, 150 mg, 200 mg tablets; 10 mg/mL, 40 mg/mL suspension; 2 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Fungistatic; may also be fungicidal depending on concentration. Interferes with formation of ergosterol, the principal sterol
         in the fungal cell membrane that, when depleted, interrupts membrane function.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Antifungal properties are related to the drug effect on the fungal cell membrane functioning.</p>
<h1><a name="uses">Uses</a></h1>
<p>Cryptococcal meningitis and oropharyngeal and systemic candidiasis, both commonly found in AIDS and other immunocompromised
         patients; vaginal candidiasis.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to fluconazole or other azole antifungals; pregnancy (category C), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>AIDS or malignancy; hepatic impairment.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Oropharyngeal Candidiasis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 200 mg day 1, then 100 mg q.d. <small>x</small> 2 wk<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IV</span> 36 mg/kg/d<br/><br/><span class="indicationtitle">Esophageal Candidiasis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 200 mg day 1, then 100 mg q.d. <small>x</small> 3 wk<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IV</span> 36 mg/kg/d<br/><br/><span class="indicationtitle">Systemic Candidiasis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 400 mg day 1, then 200 mg q.d. <small>x</small> 4 wk<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IV</span> 36 mg/kg/d<br/><br/><span class="indicationtitle">Vaginal Candidiasis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 150 mg <small>x</small> 1 dose<br/><br/><span class="indicationtitle">Cryptococcal Meningitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 400 mg day 1, then 200 mg q.d. <small>x</small> 1012 wk<br/><span class="rdage">Child:</span> <span class="rdroute">PO/IV</span> 36 mg/kg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Take this medication for the full course of therapy, which may take weeks or months.</li>
<li>Take next dose as soon as possible if you miss a dose; however, do not take a dose if it is almost time for next dose. Do
            not double dose.
         </li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Continuous:</span> Packaged ready for use as a 2 mg/mL solution. Remove wrapper just prior to use.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Continuous:</span> Give at a maximum rate of approximately 200 mg/h. Give after hemodialysis is completed.  
               </p>
<ul>
<li>Do not use IV admixtures of fluconazole and other medications.</li>
</ul>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Trimethoprim-sulfamethoxazole.</b>
<span class="incompattype">Y-site:</span>
<b>Amphotericin B,</b>
<b>amphotericin B cholesteryl,</b>
<b>ampicillin,</b>
<b>calcium gluconate,</b>
<b>ceftazidime,</b>
<b>ceftriaxone,</b>
<b>cefuroxime,</b>
<b>chloramphenicol,</b>
<b>clindamycin,</b>
<b>diazepam,</b>
<b>digoxin,</b>
<b>erythromycin,</b>
<b>furosemide,</b>
<b>haloperidol,</b>
<b>hydroxyzine,</b>
<b>imipenem-cilastatin,</b>
<b>pentamidine,</b>
<b>piperacillin,</b>
<b>ticarcillin,</b>
<b>trimethoprim-sulfamethoxazole.</b>
</p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache. <span class="typehead">GI:</span> Nausea, vomiting, abdominal pain, diarrhea, increase in AST in patients with cryptococcal meningitis and AIDS. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Increased PT in patients on <b>warfarin;</b> may increase <b>alosetron,</b>
<b>bexarotene,</b>
<b>phenytoin,</b>
<b>cevimeline,</b>
<b>cilostazol,</b>
<b>cyclosporine,</b>
<b>dofetilide,</b>
<b>haloperidol,</b>
<b>levobupivicaine,</b>
<b>modafinil,</b>
<b>zonisamide</b> levels and toxicity; hypoglycemic reactions with <span class="classification">oral sulfonylureas</span>; decreased fluconazole levels with <b>rifampin,</b>
<b>cimetidine;</b> may prolong the effects of <b>fentanyl,</b>
<b>alfentanil,</b>
<b>methadone;</b> increased ergotamine toxicity with <b>dihydroergotamine,</b>
<b>ergotamine.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 90% absorbed from GI tract. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Distribution:</span> Widely distributed, including CSF. <span class="typehead">Metabolism:</span> 11% of dose metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. <span class="typehead">Half-Life:</span> 2050 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for allergic response. Patients allergic to other azole antifungals may be allergic to fluconazole.</li>
<li>Lab tests: Monitor BUN, serum creatinine, and liver function.</li>
<li>
            							Note: Drug may cause elevations of the following laboratory serum values: ALT, AST, alkaline phosphatase, bilirubin.
            						
         </li>
<li>Monitor for S&amp;S of hepatotoxicity.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Monitor carefully for loss of glycemic control if diabetic.</li>
<li>Inform physician of all medications being taken.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>